Lymphoma Reagents | abinScience

Home > Featured Products > Oncology Research > Lymphoma

Lymphomas encompass a diverse group of B-cell and T-cell malignancies. Targeted therapies — anti-CD20, CD19 CAR-T, CD30 ADCs, BTK inhibitors, and BCL2 antagonists — have transformed outcomes. abinScience offers an extensive panel of CD20, CD19, CD30, CD47, CD38, BCL2, and immune checkpoint reagents for lymphoma research. RUO

Key Biomarkers & Targets

CD20

MS4A1

B-cell marker targeted by rituximab, obinutuzumab, and ofatumumab. 267 antibodies including biosimilar-grade reference proteins.

Antibodies • Biosimilars

CD19

B-Lymphocyte Antigen

Primary CAR-T target for DLBCL and ALL (tisagenlecleucel, axicabtagene). 208 antibodies and biosimilar proteins.

Antibodies • Biosimilars

CD30

TNFRSF8

Hallmark of Hodgkin lymphoma and ALCL; ADC target (brentuximab vedotin). 194 antibodies and recombinant proteins.

Antibodies • Proteins

CD47

“Don’t Eat Me” Signal

Macrophage immune checkpoint; magrolimab-class therapeutics under development for NHL. 78 antibodies and biosimilar proteins.

Antibodies • Biosimilars

BCL2

B-Cell Lymphoma 2

Anti-apoptotic protein targeted by venetoclax in CLL and MCL. BCL2 overexpression defines BCL2-rearranged follicular lymphoma. 23 products.

Antibodies • Proteins

CD38 / CD22

Surface Targets

CD38 (daratumumab target); CD22 (inotuzumab ADC target). 340+ combined antibodies and biosimilars across both targets.

Antibodies • Biosimilars

Why Researchers Choose abinScience for Lymphoma

B-Cell Surface Target LibraryCD19, CD20, CD22, CD79a/b antibodies and biosimilar proteins for the most studied B-cell lymphoma therapeutic targets in one catalog.

CAR-T Target ValidationCD19, CD20, CD22, and BCMA recombinant proteins for CAR construct binding, T-cell cytotoxicity assays, and antigen density profiling.

Hodgkin & ALCL PanelCD30, CD15, PD-L1, and MHC class II antibodies for Hodgkin lymphoma and anaplastic large cell lymphoma characterization.

Innate Immune CheckpointCD47 and SIRPα antibodies and research-grade biosimilar proteins with ELISA and FACS validation.

Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

B-cell lymphoma immunophenotyping: Use CD20, CD19, CD10, BCL6, BCL2, and Ki-67 antibodies (IHC/FC) to classify DLBCL into GCB vs. non-GCB subtypes per the Hans algorithm.
CAR-T antigen screening: Profile CD19 and CD22 surface density on lymphoma cell lines and patient samples with our antibodies (FC) and recombinant proteins to predict CAR-T efficacy.
CD47-SIRPα axis research: Use recombinant CD47 and SIRPα proteins for binding kinetics (SPR/BLI) and anti-CD47 antibodies for phagocytosis assays studying macrophage checkpoint blockade.
Venetoclax resistance profiling: Assess BCL2, BCL-XL, and MCL1 expression levels by WB to understand apoptotic resistance mechanisms in CLL and MCL post-venetoclax treatment.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Do you carry rituximab biosimilar reference proteins?

Yes. Research-grade rituximab (anti-CD20) biosimilar proteins with ELISA, FACS, and Functional assay validation.

Do you carry antibodies for DLBCL classification?

Antibodies for CD10, BCL6, MUM1/IRF4, BCL2, and Ki-67 available. See product pages for validated applications per clone.

Do you have CD47 reagents for phagocytosis assays?

Research-grade anti-CD47 biosimilar antibodies (magrolimab, lemzoparlimab; ELISA/FACS/Functional assay validated). Detection antibodies (e.g., clone B6H12) and recombinant CD47 proteins (His/Fc-tagged) also available.

What CD30 reagents are available for Hodgkin lymphoma?

Anti-CD30/TNFRSF8 antibodies and recombinant CD30 proteins available. Research-grade brentuximab biosimilar with ELISA and FACS validation.

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.